Alexion's rare blood disorder drug succeeds in late-stage study

March 15 (Reuters) - Alexion Pharmaceuticals Inc said its experimental drug, ALXN1210, met the main goal in a late-stage study in patients with a rare blood disorder.

The drug, ALXN1210, was being tested against the company's flagship drug Soliris. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Maju Samuel)